Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification
Our real-world study supports the potential short-term benefits of afl8 in improving anatomical and durability outcomes in patients with recurrent nAMD. These findings also highlight the added value of data-driven evaluations. Long-term studies are needed to confirm the effectiveness and durability of afl8 in this population.
Authors
- Yannic Pannatier Schuetz (ORCID: https://orcid.org/0009-0001-3697-9121)
- Daniela Gallo Castro (ORCID: https://orcid.org/0000-0001-5145-5126)
- Konstantinos Kitsos Kalyvianakis
- Mamadou Pathé Barry
- Anna Chiara Nascimbeni
- Nicolò Bartolomeo (ORCID: https://orcid.org/0000-0001-9522-7176)
- Baptiste Crozat
- Aude Ambresin
Institutions
- Swiss Finance Institute (CH)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1007/s40123-026-01320-5
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00